JP2018527323A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527323A5
JP2018527323A5 JP2018503151A JP2018503151A JP2018527323A5 JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5 JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503151A
Other languages
English (en)
Japanese (ja)
Other versions
JP6866345B2 (ja
JP2018527323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043267 external-priority patent/WO2017015433A2/en
Publication of JP2018527323A publication Critical patent/JP2018527323A/ja
Publication of JP2018527323A5 publication Critical patent/JP2018527323A5/ja
Application granted granted Critical
Publication of JP6866345B2 publication Critical patent/JP6866345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503151A 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用 Active JP6866345B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US62/196,170 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US62/201,067 2015-08-04
US201662355302P 2016-06-27 2016-06-27
US62/355,302 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (3)

Publication Number Publication Date
JP2018527323A JP2018527323A (ja) 2018-09-20
JP2018527323A5 true JP2018527323A5 (https=) 2019-08-08
JP6866345B2 JP6866345B2 (ja) 2021-04-28

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503151A Active JP6866345B2 (ja) 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用

Country Status (19)

Country Link
US (3) US10280231B2 (https=)
EP (1) EP3322436A4 (https=)
JP (1) JP6866345B2 (https=)
KR (1) KR102644875B1 (https=)
CN (1) CN108135976B (https=)
AU (1) AU2016297575B2 (https=)
CL (1) CL2018000182A1 (https=)
CO (1) CO2018001264A2 (https=)
EA (1) EA201890360A1 (https=)
IL (1) IL256665B2 (https=)
MX (1) MX2018000959A (https=)
MY (1) MY191081A (https=)
PE (1) PE20180774A1 (https=)
PH (2) PH12021552628A1 (https=)
SA (1) SA518390788B1 (https=)
SG (1) SG10201912593VA (https=)
TW (2) TWI733685B (https=)
UA (1) UA125433C2 (https=)
WO (1) WO2017015433A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2017015433A2 (en) * 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CN117916273A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 抗il23抗体融合蛋白及用途
WO2024140930A1 (en) * 2022-12-28 2024-07-04 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
WO2025170982A2 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
EP2116556B1 (en) * 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US9505826B2 (en) * 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX360352B (es) 2012-02-15 2018-10-30 Hoffmann La Roche Cromatografia de afinidad basada en receptores fc.
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
WO2015100246A1 (en) * 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
WO2017015433A2 (en) * 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Similar Documents

Publication Publication Date Title
JP2018527323A5 (https=)
JP6703560B2 (ja) 静電的ステアリング(electrostatic steering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
HRP20191968T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
CN108601830B (zh) 双特异性抗体平台
JP2020508655A5 (https=)
CN109641949B (zh) 促进选择性轻链配对的多特异性抗体
JP2012514997A5 (https=)
JP2015528003A5 (https=)
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
JP2017509335A5 (https=)
JP2019525738A5 (https=)
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
JP2020515518A5 (https=)
JP2016507525A5 (https=)
JP2017504578A5 (https=)
JP2017512063A5 (https=)
JP2021500348A (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
EP3630811A1 (en) Heterodimerizing ig domains
JP2022009816A5 (https=)
IL302575A (en) IL-2R BETA GAMMA c BINDING COMPOUNDS AND USES THEREOF
US20260078202A1 (en) Orthogonal mutations for heterodimerization
BR112021000416A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38
RU2009126545A (ru) МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН
CN120187749A (zh) 具有可活化效应结构域的重组结合蛋白